Tip:
Highlight text to annotate it
X
Turning the Tide CHENGDU, CHINA
This hospital is of huge scale. We have more than 4,300 beds.
Globally, China accounts for more than half of the new cases – and deaths – from liver cancer.
Some old technologies can be intrusive.
There’s a high cost and burden for the patients.
Some new technologies are more affordable, especially the ElastPQ from Philips.
The ElastPQ is non-intrusive, while providing more detailed information for diagnosis.
We began a research project with Philips’ Ultrasound Institute on liver cancer elasticity two years ago.
We have sampled over 1,200 cases.
So far, we’ve already published one scientific paper.
Our paper supports the new technology and also details the clinical applications.
So that everyone can repeat the same results.
The Philips team has a lot of resources, including scientists with engineering backgrounds.
Having joined forces, we’re bridging the gap to match technology with actual clinical needs.
We raise new questions in the process of solving problems.
This evolving cycle helps us to continuously innovate.
Today the focus is on liver cancer, but I hope to expand our collaboration to other areas.
Our ultimate goal is to provide faster and more accurate diagnosis and treatment for patients.